FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894099206> ?p ?o ?g. }

• W2894099206 endingPage "6414" @default.
• W2894099206 startingPage "6405" @default.
• W2894099206 abstract "Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials Xiaonan Yin,1,* Yuan Yin,1,* Chaoyong Shen,1 Huijiao Chen,2 Jiang Wang,1 Zhaolun Cai,1 Zhixin Chen,1 Bo Zhang1 1Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China; 2Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China *These authors contributed equally to this work Background: Regorafenib is a novel multikinase inhibitor (MKI) approved for use in the treatment of metastatic colorectal cancer (CRC), treatment-refractory gastrointestinal stromal tumors, and other solid tumor malignancies. However, the adverse events (AEs) associated with regorafenib have not been systematically investigated. Hence, we performed a meta-analysis to identify AEs associated with regorafenib in patients with advanced solid tumors.Methods: The databases of PubMed, MEDLINE, and Embase and abstracts presented in American Society of Clinical Oncology annual meetings were searched for relevant publications from January 2004 to September 2017. Eligible studies were limited to prospective randomized controlled trials (RCTs) that evaluate the use of regorafenib in patients with advanced solid tumors. Incidence, relative risk (RR), and 95% CIs were calculated using a random or fixed effects model on the basis of the heterogeneity of the included studies.Results: A total of 2,065 patients from six RCTs were included, and 1,340 of them received regorafenib and 725 received a placebo. Sixteen all-grade AEs and 15 high-grade AEs were investigated for their association with regorafenib. Results showed that hand–foot skin reaction (HFSR; 54%), diarrhea (33%), fatigue (32%), hypertension (31%), oral mucositis (28%), and anorexia (23%) were the most frequent clinical AEs. The most common high-grade (grade, $3) AEs were HFSR (16%), hypertension (13%), fatigue (6%), increased aspartate aminotransferase (AST; 6%), and hypophosphatemia (6%). Pooled RR showed that the use of regorafenib was associated with an increased risk of developing AEs. Subgroup analysis based on the prior MKI treatment showed that prior MKI treatment was associated with an increased incidence of all-grade anorexia (P=0.03) and a reduced incidence of high-grade increased AST (P=0.04). However, subgroup analysis based on the tumor type showed that no significant differences were found when comparing the RR of all-grade and high-grade AEs in patients with CRC or non-CRC.Conclusion: The meta-analysis systematically investigated regorafenib-associated AEs. Knowledge of these AEs is essential for minimizing treatment-related toxicities and improving clinical outcomes. Keywords: regorafenib, adverse event, AE, safety, multikinase inhibitor, meta-analysis&nbsp" @default.
• W2894099206 created "2018-10-05" @default.
• W2894099206 creator A5011877804 @default.
• W2894099206 creator A5016975188 @default.
• W2894099206 creator A5017825677 @default.
• W2894099206 creator A5021452379 @default.
• W2894099206 creator A5021847587 @default.
• W2894099206 creator A5022483317 @default.
• W2894099206 creator A5074350121 @default.
• W2894099206 creator A5075394139 @default.
• W2894099206 date "2018-10-01" @default.
• W2894099206 modified "2023-10-17" @default.
• W2894099206 title "Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials" @default.
• W2894099206 cites W1480729244 @default.
• W2894099206 cites W1964435302 @default.
• W2894099206 cites W1965571386 @default.
• W2894099206 cites W1968209756 @default.
• W2894099206 cites W1971837077 @default.
• W2894099206 cites W1974791708 @default.
• W2894099206 cites W1980323556 @default.
• W2894099206 cites W1986215651 @default.
• W2894099206 cites W2038693293 @default.
• W2894099206 cites W2062406852 @default.
• W2894099206 cites W2064263770 @default.
• W2894099206 cites W2111851685 @default.
• W2894099206 cites W2116922255 @default.
• W2894099206 cites W2119886101 @default.
• W2894099206 cites W2146900037 @default.
• W2894099206 cites W2147834058 @default.
• W2894099206 cites W2157823046 @default.
• W2894099206 cites W2332019204 @default.
• W2894099206 cites W2472847770 @default.
• W2894099206 cites W2507937105 @default.
• W2894099206 cites W2537836937 @default.
• W2894099206 cites W2560499218 @default.
• W2894099206 doi "https://doi.org/10.2147/ott.s156760" @default.
• W2894099206 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6174311" @default.
• W2894099206 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30323618" @default.
• W2894099206 hasPublicationYear "2018" @default.
• W2894099206 type Work @default.
• W2894099206 sameAs 2894099206 @default.
• W2894099206 citedByCount "21" @default.
• W2894099206 countsByYear W28940992062019 @default.
• W2894099206 countsByYear W28940992062020 @default.
• W2894099206 countsByYear W28940992062021 @default.
• W2894099206 countsByYear W28940992062022 @default.
• W2894099206 countsByYear W28940992062023 @default.
• W2894099206 crossrefType "journal-article" @default.
• W2894099206 hasAuthorship W2894099206A5011877804 @default.
• W2894099206 hasAuthorship W2894099206A5016975188 @default.
• W2894099206 hasAuthorship W2894099206A5017825677 @default.
• W2894099206 hasAuthorship W2894099206A5021452379 @default.
• W2894099206 hasAuthorship W2894099206A5021847587 @default.
• W2894099206 hasAuthorship W2894099206A5022483317 @default.
• W2894099206 hasAuthorship W2894099206A5074350121 @default.
• W2894099206 hasAuthorship W2894099206A5075394139 @default.
• W2894099206 hasBestOaLocation W28940992061 @default.
• W2894099206 hasConcept C121608353 @default.
• W2894099206 hasConcept C126322002 @default.
• W2894099206 hasConcept C142724271 @default.
• W2894099206 hasConcept C143998085 @default.
• W2894099206 hasConcept C168563851 @default.
• W2894099206 hasConcept C17744445 @default.
• W2894099206 hasConcept C197934379 @default.
• W2894099206 hasConcept C199539241 @default.
• W2894099206 hasConcept C204787440 @default.
• W2894099206 hasConcept C27081682 @default.
• W2894099206 hasConcept C2776248978 @default.
• W2894099206 hasConcept C2779473830 @default.
• W2894099206 hasConcept C44249647 @default.
• W2894099206 hasConcept C526805850 @default.
• W2894099206 hasConcept C71924100 @default.
• W2894099206 hasConcept C82789193 @default.
• W2894099206 hasConcept C95190672 @default.
• W2894099206 hasConceptScore W2894099206C121608353 @default.
• W2894099206 hasConceptScore W2894099206C126322002 @default.
• W2894099206 hasConceptScore W2894099206C142724271 @default.
• W2894099206 hasConceptScore W2894099206C143998085 @default.
• W2894099206 hasConceptScore W2894099206C168563851 @default.
• W2894099206 hasConceptScore W2894099206C17744445 @default.
• W2894099206 hasConceptScore W2894099206C197934379 @default.
• W2894099206 hasConceptScore W2894099206C199539241 @default.
• W2894099206 hasConceptScore W2894099206C204787440 @default.
• W2894099206 hasConceptScore W2894099206C27081682 @default.
• W2894099206 hasConceptScore W2894099206C2776248978 @default.
• W2894099206 hasConceptScore W2894099206C2779473830 @default.
• W2894099206 hasConceptScore W2894099206C44249647 @default.
• W2894099206 hasConceptScore W2894099206C526805850 @default.
• W2894099206 hasConceptScore W2894099206C71924100 @default.
• W2894099206 hasConceptScore W2894099206C82789193 @default.
• W2894099206 hasConceptScore W2894099206C95190672 @default.
• W2894099206 hasLocation W28940992061 @default.
• W2894099206 hasLocation W28940992062 @default.
• W2894099206 hasLocation W28940992063 @default.
• W2894099206 hasLocation W28940992064 @default.
• W2894099206 hasOpenAccess W2894099206 @default.
• W2894099206 hasPrimaryLocation W28940992061 @default.
• W2894099206 hasRelatedWork W1539974851 @default.

• next